A quality improvement initiative for achieving target tacrolimus concentration in renal transplant recipients: A quality improvement article,

Tacrolimus is a cornerstone immunosuppressive agent in solid organ transplantation due to its efficacy in preventing rejection. Achieving optimal tacrolimus levels remains challenging and limited studies have explored quality improvement (QI) initiatives aimed at optimizing tacrolimus trough levels. We conducted a QI initiative at Taichung Veterans General Hospital targeting tacrolimus level optimization in renal transplant recipients between January 2015 and January 2019. This multifaceted intervention included: physician reminders integrated into the Electronic Health Information System (EHIS) to monitor trough levels and variability, patient engagement through a mobile application displaying immunosuppressant levels, and automated tacrolimus concentration measurement to reduce ordering errors. Outcomes were descriptively evaluated before and after the interventions, including measurement accuracy, biopsy-proven acute rejection (BPAR) rates, and intrapatient variability (IPV), without formal statistical comparison. The implementation of automated tacrolimus measurement eliminated ordering errors, leading to an estimated cost saving of $78,911.3 over 2 years. A numerical decrease in BPAR incidence was observed, from 9% pre-intervention to 0% post-intervention. Tacrolimus intrapatient variability (IPV) also showed a decreasing trend, from 26.45% in 2019 to 18.7% in 2022. Physician reminders and patient engagement interventions contributed to improved monitoring but had a less pronounced impact on acute rejection rates. This study describes a structured QI initiative, including the automation of tacrolimus concentration measurements, and its association with improvements in therapeutic drug monitoring processes in renal transplant recipients. These findings suggest a potential role for mistake-proofing mechanisms in enhancing measurement accuracy and contributing to cost savings. Observed changes in rejection rates were descriptive and should be interpreted with caution given the small number of events.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-04-24
DOI
https://doi.org/10.1097/md.0000000000048443
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A quality improvement initiative for achieving target tacrolimus concentration in renal transplant recipients: A quality improvement article,

Cheng‐Hsu Chen, Ching-Yao Cheng, Shang‐Feng Tsai, Hsiu-Mei Chen et al.
Medicine
Renal Transplantation Outcomes and Treatments
article

A quality improvement initiative for achieving target tacrolimus concentration in renal transplant recipients: A quality improvement article,

Cheng‐Hsu Chen, Ching-Yao Cheng, Shang‐Feng Tsai, Hsiu-Mei Chen, Kuo-Hsiung Shu, Ming-Ju Wu
article en

Abstract

Tacrolimus is a cornerstone immunosuppressive agent in solid organ transplantation due to its efficacy in preventing rejection. Achieving optimal tacrolimus levels remains challenging and limited studies have explored quality improvement (QI) initiatives aimed at optimizing tacrolimus trough levels. We conducted a QI initiative at Taichung Veterans General Hospital targeting tacrolimus level optimization in renal transplant recipients between January 2015 and January 2019. This multifaceted intervention included: physician reminders integrated into the Electronic Health Information System (EHIS) to monitor trough levels and variability, patient engagement through a mobile application displaying immunosuppressant levels, and automated tacrolimus concentration measurement to reduce ordering errors. Outcomes were descriptively evaluated before and after the interventions, including measurement accuracy, biopsy-proven acute rejection (BPAR) rates, and intrapatient variability (IPV), without formal statistical comparison. The implementation of automated tacrolimus measurement eliminated ordering errors, leading to an estimated cost saving of $78,911.3 over 2 years. A numerical decrease in BPAR incidence was observed, from 9% pre-intervention to 0% post-intervention. Tacrolimus intrapatient variability (IPV) also showed a decreasing trend, from 26.45% in 2019 to 18.7% in 2022. Physician reminders and patient engagement interventions contributed to improved monitoring but had a less pronounced impact on acute rejection rates. This study describes a structured QI initiative, including the automation of tacrolimus concentration measurements, and its association with improvements in therapeutic drug monitoring processes in renal transplant recipients. These findings suggest a potential role for mistake-proofing mechanisms in enhancing measurement accuracy and contributing to cost savings. Observed changes in rejection rates were descriptive and should be interpreted with caution given the small number of events.

MedicineVol. 105(17)
National Chung Hsing University (TW), Tunghai University (TW), China Medical University (TW), Taichung Veterans General Hospital (TW), Taichung Hospital (TW)
Openalex Percentile: Top 14%
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.